Search Results - Funda Meric-Bernstam

Refine Results
  1. 1

    Antibody-drug conjugates in lung cancer: dawn of a new era? by Niamh Coleman, Timothy A. Yap, John V. Heymach, Funda Meric-Bernstam, Xiuning Le

    Published in npj Precision Oncology (2023-01-01)
    Get full text
    Article


  2. 2

    Strategies for improving the management of immune-related adverse events by James L Gulley, Patrick Hwu, Gennaro Ciliberto, Aung Naing, Funda Meric-Bernstam, Michael B Atkins, Joud Hajjar

    Published in Journal for ImmunoTherapy of Cancer (2020-10-01)
    Get full text
    Article


  3. 3

    Molecular differences between younger versus older ER-positive and HER2-negative breast cancers by Tao Qing, Thomas Karn, Mariya Rozenblit, Julia Foldi, Michal Marczyk, Naing Lin Shan, Kim Blenman, Uwe Holtrich, Kevin Kalinsky, Funda Meric-Bernstam, Lajos Pusztai

    Published in npj Breast Cancer (2022-11-01)
    Get full text
    Article


  4. 4

    Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition by Niamh Coleman, Vivek Subbiah, Shubham Pant, Keyur Patel, Sinchita Roy-Chowdhuri, Sireesha Yedururi, Amber Johnson, Timothy A. Yap, Jordi Rodon, Kenna Shaw, Funda Meric-Bernstam

    Published in npj Precision Oncology (2021-12-01)
    Get full text
    Article


  5. 5

    143 Correlating RNA-seq detection and IHC staining of potential antibody-drug conjugate (ADC) targets: HER3, HER2, TROP2, Nectin4, and aFLR by Funda Meric-Bernstam, Nathan Fowler, Ekaterina Postovalova, Zhongmin Xiang, Krystle Nomie, Vladimir Kushnarev, Alexander Bagaev, Danil Stupichev, Kirill Kryukov, Suren Davitavyan, Monique Johnson, Basavaraja Uddajjara Shanthappa

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  6. 6

    Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial by Mohamed A. Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A. Gurses, Ashabari Sprenger, Yanyan Tian, Mohamed H. Derbala, Isabella Glitza Oliva, Funda Meric-Bernstam, Sapna P. Patel

    Get full text
    Article


  7. 7

    Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer by Vivek Subbiah, Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria Cabanillas, Mimi Hu, Luz E. Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu

    Published in npj Precision Oncology (2024-03-01)
    Get full text
    Article


  8. 8

    584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies by Aung Naing, Funda Meric-Bernstam, Shubham Pant, Milind Javle, Juhee Song, Anas Alshawa, Bettzy Stephen, Abdulrazzak Zarifa, Jordi Rodon, Yali Yang, Robert A Wolff, Anne Knisely, Van Morris, Jibran Ahmed

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  9. 9

    Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors by Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A. Piha‐Paul, John Wright, Senait N. Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric‐Bernstam, Aung Naing

    Published in Cancer Medicine (2024-02-01)
    Get full text
    Article


  10. 10

    Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation by Anca Chelariu-Raicu, Sarina A. Piha-Paul, Mariana Chavez-MacGregor, Jason Johnson, Raymond Sawaya, Mary Frances McAleer, Alissa Nguyen, Audrey Hartnett, Apostolia M. Tsimberidou, Funda Meric-Bernstam, Ecaterina E. Dumbrava

    Get full text
    Article


  11. 11

    Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan by Ming Zhao, Timothy P. DiPeri, Maria Gabriela Raso, Xiaofeng Zheng, Yasmeen Qamar Rizvi, Kurt W. Evans, Fei Yang, Argun Akcakanat, Marco Roberto Estecio, Debu Tripathy, Ecaterina E. Dumbrava, Senthil Damodaran, Funda Meric-Bernstam

    Published in npj Breast Cancer (2023-08-01)
    Get full text
    Article


  12. 12

    FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. by Denis L Jardim, Jennifer J Wheler, Kenneth Hess, Apostolia M Tsimberidou, Ralph Zinner, Filip Janku, Vivek Subbiah, Aung Naing, Sarina A Piha-Paul, Shannon N Westin, Sinchita Roy-Chowdhuri, Funda Meric-Bernstam, David S Hong

    Published in PLoS ONE (2014-01-01)
    Get full text
    Article


  13. 13

    RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation by Vladimir Kushnarev, Danil Stupichev, Suren Davitavyan, Kirill Kriukov, Basavaraja U. Shanthappa, Anna Butusova, Sofia Menshikova, Anna Belozerova, Anastasia Shvyrkova, Arina Tkachuk, Olga Khatenkova, Linda Balabanian, Ekaterina Postovalova, Jochen K. Lennerz, Funda Meric-Bernstam, Alexander Bagaev

    Published in Scientific Reports (2025-08-01)
    Get full text
    Article


  14. 14

    BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study by Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S. Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa Lamki Busaidy, Milind Javle, Lauren Averett Byers, John V. Heymach, Funda Meric-Bernstam, Vivek Subbiah

    Published in npj Precision Oncology (2023-02-01)
    Get full text
    Article


  15. 15

    RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study by Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell, Amber M Johnson, Sarina A. Piha-Paul, Isabella C. Glitza Oliva, Shiao-Pei Weathers, Maria Cabanillas, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah

    Published in Molecular Cancer (2024-03-01)
    Get full text
    Article


  16. 16

    Predicting pathologic ≥N2 disease in women with breast cancer by Kerollos Nashat Wanis, Wenli Dong, Yu Shen, Funda Meric-Bernstam, Taiwo Adesoye, Henry M. Kuerer, Abigail S. Caudle, Nina Tamirisa, Sarah M. DeSnyder, Susie X. Sun, Isabelle Bedrosian, Puneet Singh, Solange E. Cox, Kelly K. Hunt, Rosa F. Hwang

    Published in npj Breast Cancer (2025-05-01)
    Get full text
    Article


  17. 17

    Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer by Turcin Saridogan, Argun Akcakanat, Ming Zhao, Kurt W. Evans, Erkan Yuca, Stephen Scott, Bryce P. Kirby, Xiaofeng Zheng, Min Jin Ha, Huiqin Chen, Patrick K. S. Ng, Timothy P. DiPeri, Gordon B. Mills, Jordi Rodon Ahnert, Senthil Damodaran, Funda Meric-Bernstam

    Published in Scientific Reports (2023-11-01)
    Get full text
    Article


  18. 18

    First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models by Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava, Manuel Aivado, Funda Meric-Bernstam

    Published in Breast Cancer Research (2021-03-01)
    Get full text
    Article


  19. 19

    Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial by Funda Meric-Bernstam, Sun Young Rha, Erika Hamilton, Yoon-Koo Kang, Diana L. Hanna, Syma Iqbal, Keun-Wook Lee, Jeeyun Lee, Muralidhar Beeram, Do-Youn Oh, Jorge Chaves, Rachel A. Goodwin, Jaffer A. Ajani, Lin Yang, Rajen Oza, Elena Elimova

    Published in Nature Communications (2025-05-01)
    Get full text
    Article


  20. 20

    Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies by Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma, James Allison, Funda Meric-Bernstam, David S. Hong

    Published in Journal for ImmunoTherapy of Cancer (2017-04-01)
    Get full text
    Article


Search Tools: